EasyBlog

This is some blog description about this site

COPENHAGEN, OCTOBER 22, 2018 – UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today announced positive results from a Phase 1 Sensitization Study in 240 healthy adult volunteers with ATx201. The study was conducted in the US under IND as a randomized and placebo-controlled study. In comparing the active group to placebo, no signs of sensitization were observed, and no subjects showed any signs of unexpected adverse events.

Dr. Philippe Prokocimer, Chief Medical Officer of UNION commented: "The positive outcome of the sensitization study complements prior safety studies with ATx201, in both animals and humans. We are pleased that the studies support the safety and tolerability of ATx201 in both healthy and abraded skin".

Dr. Morten Sommer, the Chief Scientific Officer further added: “The safety and tolerability of ATx201 is of paramount importance given our focus on atopic dermatitis which is common in children. We express our genuine appreciation to the volunteers whose time and effort are helping the development of a much needed new treatment option”. ATx201 is currently being tested in atopic dermatitis patients, for which results are soon expected”.

UNION has previously completed two other Phase 1 studies with ATx201. One of them evaluated the ATx201 irritation potential in 36 healthy adult volunteers. All treatment regimens came out with positive results in both intact and abraded skin after daily applications for 21 days. The other Phase 1 study assessed the systemic safety, local tolerability of three dermal formulations of ATx201 in 30 healthy volunteers using a split-body design. The volunteers were treated twice daily with either ATx201 or placebo during a 7-day period. This study also demonstrated good safety as well as low systemic absorption of ATx201.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements

Continue reading

COPENHAGEN, OCTOBER 09, 2018 - Dr. Rasmus Toft-Kehler, Chief Executive Officer of AntibioTx, announced this week in Copenhagen that the company has officially changed its name to UNION therapeutics as of October 5, 2018.

”The new company name – UNION – reflects recent progress on the technology platform and expansion of expertise”, explained Dr. Toft-Kehler, and commented: “Our chemistry platform has provided compounds with very interesting immunological properties in combination with antimicrobial activity. The unique properties of our compounds will enable us to develop innovative treatments across a broad spectrum of diseases” and further adds “the expansion into immunology represents a new era for the company with great prospects for both patients and society”.

UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both antimicrobial and immunomodulatory effects. UNION will initially focus on the treatment of inflammatory skin diseases, however, the chemistry platform and its versatile new modes of action is expected to be applicable across a wide range of diseases. The leadership team of UNION has invented and successfully developed more than 10 FDA-approved medicines. In 2017, these medicines saved thousands of lives and generated revenues of more than 5 Billion USD. UNION is headquartered in Copenhagen (Denmark) with a US subsidiary and a global team.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutic A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, JULY 01 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Umar Hayat, Ph.D. as VP of CMC and Supply Chain.

Dr. Morten Sommer, Chief Scientific Officer of AntibioTx commented: ”As the company continues to expand into new areas the role of CMC becomes increasingly important for our success. We are delighted to have engaged with such a capacity as Umar and are looking very much forward working with him on the team”

Umar Hayat, Ph.D. will be the VP of CMC and Supply Chain at AntibioTx and will, in particular, be responsible for the late-stage clinical part of CMC. Dr. Hayat has more than 18 years of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with Relypsa, Anacor and Transcept Pharmaceuticals. Played a pivotal role in the CMC development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis. Umar received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, JUNE 25, 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders, has with the addition of two preclinical studies (Ocular Irritation and Phototoxicity) further strengthened ATx201’s safety profile for topical use.

The Ocular Irritation in vitro study evaluated the potential for causing eye damage using gold standard tests. ATx201 2%, 4% and Placebo were all classified as a non-irritant supporting the safety profile of ATx201 with regards to eye contact.

The Phototoxicity in vivo study determined the potential phototoxic effects of ATx201 Gel formulations when administered topically on the skin of hairless mice, followed by exposure to ultraviolet B, ultraviolet A and visible light.

The results provoked no cutaneous phototoxicity following topical dermal administration of the placebo or 2% or 4% ATx201. Dr. Morten Sommer, CSO of AntibioTx concluded: “The safety of ATx201 is of critical importance due to our focus on diseases that are very common in the pediatric population”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, APRIL 02, 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Morten Boesen as CFO and Mads Jellingso as VP of Commercialization

Dr. Rasmus Toft-Kehler, CEO and Co-founder commented “Strengthening our management team is critical for the company’s continued development and long-term success. What is common for Morten Boesen and Mads Jellingso is that they bring important experience and expertise from globally leading institutions within their respective fields. I am excited that they have decided to join our team at AntibioTx to support the next stage of our venture”.

Morten Boesen will take on the role as Chief Financial Officer, starting from April 1, 2018. Since 2011, Mr. Boesen has worked with EQT, the leading private equity fund in the Nordics, initially as an investment manager and subsequently as an executive director in the EQT-owned global retailer, Tiger. Prior to that, Mr. Boesen worked as a management consultant with McKinsey & Company, in the M&A advisory of Nordea Bank, and in the finance department of Novozymes, the world leader in industrial biotechnology. Mr. Boesen holds a M.Sc. in Finance and Accounting from Copenhagen Business School.

Mads Jellingso will take on the role of Vice President of Commercialization. Mr. Jellingso joins AntibioTx from Novo Nordisk, where he most recently specialized in global market access and innovative contracting. Mr. Jellingso also has experience from the legal affairs and finance departments of Novo Nordisk, and prior to that he worked as a management consultant with McKinsey & Company and management advisor in Nordea Market. Mr. Jellingso holds a M.Sc. in Economics from University of Copenhagen.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

 

Continue reading

News